StockData
Artiva Biotherapeutics, Inc. logo

Artiva Biotherapeutics, Inc. (ARTV) stock

ARTVNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$3.77−0.09 (-2.33%)

Close on Nov 18, 2026Market cap $184.32MP/E –Yield –

Artiva Biotherapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Artiva Biotherapeutics's operating income for the twelve months ending Jun 30, 2026 was -$96.15M. For fiscal 2025 it was -$89.81M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$89.81M–
FY2024Dec 31, 2024-$67.28M–
FY2023Dec 31, 2023-$30.67M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$26.89M–
Q1 FY2026Mar 31, 2026-$24.43M–
Q4 FY2025Dec 31, 2025-$21.93M–
Q3 FY2025Sep 30, 2025-$22.90M–
Q2 FY2025Jun 30, 2025-$22.81M–
Q1 FY2025Mar 31, 2025-$22.17M–
Q4 FY2024Dec 31, 2024-$18.27M–
Q3 FY2024Sep 30, 2024-$18.34M-269.6%
Q2 FY2024Jun 30, 2024-$16.19M–
Q1 FY2024Mar 31, 2024-$14.49M–
Q4 FY2023Dec 31, 2023-$11.97M–
Q3 FY2023Sep 30, 2023$10.81M–
Q2 FY2023Jun 30, 2023-$11.82M–

More Artiva Biotherapeutics figures

See a number that looks wrong?